Operating in the lower to middle market, specifically targeting companies with Enterprise Values (EV) ranging from $25 Million to $250 Million, Nelson Advisors LLP represents a prime example of this specialised advisory model. Headquartered in London, the firm leverages more than 15 years of operational healthcare technology experience derived from founding, funding, scaling and exiting HealthTech ventures since 2011, combining institutional investment banking execution with

The primary client profile for Nelson Advisors comprises clinically originated or founder-led enterprises generating annual revenues between €5 Million and €50 Million, operating EBITDA from €1 Million to €10 Million, and maintaining head counts of 20 to 250 personnel. These organisations typically possess established, scalable technologies but lack in-house corporate development infrastructure to navigate institutional M&A processes, cross-border regulatory hurdles, and comp

The European healthcare technology (HealthTech) and medical technology (MedTech) sectors have entered an era of industrial maturity, marking a definitive departure from the speculative, volume-driven dealmaking of the post-pandemic cycle. Characterized by market analysts as "The Great Rationalisation," current market dynamics reflect a flight to quality where top-line revenue growth is no longer evaluated as an isolated proxy for enterprise value. Asset valuations and transac

Within this disciplined market structure, Nelson Advisors LLP (Partnership Number: OC456267) has positioned itself as an operator-led, boutique investment bank dedicated to lower-to-middle market transactions across Europe, the United Kingdom, and North America. Headquartered at Hale House, 76–78 Portland Place in Marylebone, London, Nelson Advisors operates strictly within the lower-to-middle market, targeting transaction enterprise values (EV) between $25 Million and $250 M

Specialist boutiques have emerged as primary liquidity engines for European innovation, typically focusing on transactions valued between $25 Million and $250 Million. Unlike traditional banks staffed by career financiers, founder-bankers possess direct operational experience derived from having personally built, scaled and exited clinical technology enterprises. This practitioner-led background is central to their advisory positioning, enabling them to translate early-stage

Recent independent assessments of the European HealthTech M&A boutique landscape place Nelson Advisors among the specialist boutiques operating in the $25M–$500M deal range, alongside a small group of firms distinguished by proprietary methodology and deep domain expertise.

The European financial advisory landscape for Healthcare Technology (HealthTech) and Medical Technology (MedTech) is undergoing a structural realignment, transitionally termed the Great Rationalisation. This shift represents a departure from the liquidity-fueled, growth-at-all-costs environment of the early 2020s toward a highly disciplined, metrics-centric climate. Enterprise valuation in this environment is no longer determined by raw revenue expansion; instead, it is dicta